On November 20th, the renowned business magazine Fortune released its 2024 Fortune 50 AI Innovators list, highlighting the AI companies leading in the new phase of AI technology applications. Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to be listed. Other honorees include internet giants like Alibaba, ByteDance, Meta, and Microsoft; leading companies in the chip industry such as AMD and NVIDIA; and AI emerging stars like Hugging Face and OpenAI. 

Three research institutions in Barcelona have teamed up to launch the world’s first Joint Program on Evolutionary Medical Genomics. The initiative, launched this week at an inaugural symposium in Barcelona Biomedical Research Park (PRBB), is a collaboration between the Centre for Genomic Regulation (CRG), the Department of Medicine and Life Sciences at the Universitat Pompeu Fabra (UPF), and the Institut de Biologia Evolutiva (IBE: CSIC-UPF). Spearheaded by ICREA Research Professor Manuel Irimia, the program seeks to harness evolutionary principles to better understand the molecular roots of disease and improve human health. It is backed with a provisional funding of one million euros from the Generalitat de Catalunya.

In a new review, Arizona State University researchers, working with colleagues around the world, explore how established agricultural pest management strategies could be adapted to address cancer therapy. The pioneering method opens new possibilities for controlling drug resistance and improving patient survival.

The Diagnostics Development Hub (DxD Hub), a national platform hosted by the Agency for Science, Technology and Research (A*STAR), Singapore, in collaboration with the National Institute for Environmental Studies (NIES), Japan, and the A*STAR Bioinformatics Institute (A*STAR BII), has successfully developed Steadfast, an advanced diagnostic kit for detecting the highly pathogenic H5N1 Avian Influenza Virus (AIV). This development marks a significant breakthrough in avian influenza monitoring, reinforcing global efforts in pandemic preparedness.

A new technology enhances critical modifications of glycoprotein glycans, specifically galactosylation and sialylation, by adding a “passport sequence” that promotes efficient transport through the secretory pathway. This approach improves the quality and efficiency of therapeutic glycoproteins, advancing the development of high-quality biopharmaceuticals.

University of Melbourne Associate Professor Giuseppe Barca and his team were named the winners of the Association for Computing Machinery’s Gordon Bell Prize at the SC International Conference for High Performance Computing, Networking, Storage and Analysis in Atlanta, Georgia.